Abstract:Background: Lung cancer causes 1.8 million deaths annually and has the highest cancer mortality rate, with 85% of cases being non-small cell lung cancer (NSCLC). Immunotherapy with immune checkpoint inhibitors (ICIs) has shown significant progress, using monoclonal antibodies to modulate crucial immune signals. ICIs are more effective than standard second-line chemotherapy, but reliable prognostic markers are needed. Despite promising results there is a lack of robust prognostic markers that indicate response to ICIs. Aim: The study focused on investigating the prognostic significance of complete blood count (CBC) values and the number of tumor-infiltrating lymphocytes (TILs) for NSCLC patients undergoing ICIs therapy. Methods: A retrospective review was conducted on advanced NSCLC patients treated with ICIs at Barretos Cancer Hospital (Brazil). CBC values were assessed at diagnosis, baseline (before ICI), and after three infusion cycles. TIL percentages were evaluated from diagnostic biopsies stained with hematoxylin and eosin, focusing on mononuclear cells (lymphocytes and plasma cells). Median values were used as cutoff points for CBC and TILs analysis. Demographic data (age, sex, smoking status, histology, staging, PD-L1 status, treatment) were collected. Primary outcomes, overall survival (OS) and progression-free survival (PFS), were assessed via Kaplan-Meier analysis and log-rank test, with Mann-Whitney test used for correlation analysis. Results: The study cohort included 91 patients, with adenocarcinoma being the predominant histological type (57.1%), 54.9% of whom were male, and 63.7% diagnosed at stage IV. Within the cohort, 64.9% had positive PD-L1 status and only 13.2% had never smoked. The study found significant associations between baseline CBC components and clinical outcomes. Lower neutrophil-to-lymphocyte ratios (NLR 2.00) were associated with increased PFS (p = 0.004). Furthermore, LMR counts and the percentage of TILs exhibited a differential distribution between treatment responder and non-responder groups (p = 0.004 and p = 0.050, respectively). Conclusion: Effective management of NSCLC with ICIs remains critical. This study demonstrates that specific CBC components and TILs are valuable prognostic markers in advanced NSCLC patients undergoing ICI therapy. These markers can serve as valuable and cost-effective prognostic biomarkers in guiding treatment strategies. Citation Format: Katiane Tostes, Tauana Christina Dias, Gabriela Karam Rebolho, Leticia Ferro Leal, Lidia Maria Rebolho Batista Arantes. Prognostic significance of complete blood count values and tumor- infiltrating lymphocytes in non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A007.

Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor

Prediction of Clinical Outcome in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy by Plasma Markers

Abstract 969: Non-invasive detection of plasma proteins in immune checkpoint inhibitor-treated patients with advanced non-small cell lung cancer

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP

Plasma Cytokines Interleukin-18 and C-X-C Motif Chemokine Ligand 10 Are Indicative of the Anti-Programmed Cell Death Protein-1 Treatment Response in Lung Cancer Patients

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy

Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity

CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

Abstract A007: Prognostic significance of complete blood count values and tumor-infiltrating lymphocytes in non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer

Elevated IL-6/IL-1Ra Ratio As a Prognostic Biomarker of Poor Chemotherapy Efficacy in Chinese Patients with Metastatic NSCLC, Validated in a Caucasian Patient Cohort